Ziftomenib

72 interactions 4 explained in plain English

Also sold as: Komzifti

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Ivabradine Ofloxacin Otic Octreotide Injection Oxaliplatin Injection Hydroxychloroquine

1 Contraindicated 71 Major

All (72) Contraindicated (1) Major (71)

Major

Ziftomenib Omeprazole Gastrobim Explained Reduced ziftomenib exposure and reduced efficacy of ziftomenib Details Ziftomenib Amitriptyline Elavil Explained An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Sertraline Explained An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Buprenorphine Belbuca Explained An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Amisulpride Injection Barhemsys An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Arsenic Trioxide Trisenox An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Aripiprazole Injection Abilify An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Arsenic Trioxide Injection Trisenox An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Asenapine Transdermal Patch Secuado An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Azithromycin AzaSite An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Alfuzosin UroXatral An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Anagrelide Agrylin An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Bedaquiline Sirturo An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Chloroquine Aralen® An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Dasatinib Phyrago An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Degarelix Injection Firmagon An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Deutetrabenazine Austedo An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Dexamethasone Injection Decadron Reduced ziftomenib exposure and reduced efficacy of ziftomenib Details Ziftomenib Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Reduced ziftomenib exposure and reduced efficacy of ziftomenib Details Ziftomenib Dexlansoprazole Dexilant Reduced ziftomenib exposure and reduced efficacy of ziftomenib Details Ziftomenib Disopyramide Norpace An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Dofetilide Tikosyn An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Dolasetron Anzemet An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Dolasetron Injection Anzemet An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Encorafenib Braftovi An increased risk of QT interval prolongation, reduced ziftomenib exposure and reduced efficacy of ziftomenib Details Ziftomenib Entrectinib Rozlytrek An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Eribulin Injection Halaven An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Esomeprazole Nexium Reduced ziftomenib exposure and reduced efficacy of ziftomenib Details Ziftomenib Esomeprazole Injection Nexium Reduced ziftomenib exposure and reduced efficacy of ziftomenib Details Ziftomenib Famotidine Calmicid An increased risk of QT interval prolongation and torsade de pointes, reduced ziftomenib exposure and reduced efficacy of ziftomen... Details Ziftomenib Famotidine Injection Calmicid An increased risk of QT interval prolongation and torsade de pointes, reduced ziftomenib exposure and reduced efficacy of ziftomen... Details Ziftomenib Felbamate Felbatol An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Flecainide Tambocor® An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Foscarnet Injection Foscavir An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Galantamine Razadyne An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Gemifloxacin Factive An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Glasdegib Daurismo An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Goserelin Implant Zoladex An increased risk of QT interval prolongation and torsade de pointes Details Ziftomenib Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation and torsade de pointes Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.